In a Swedish prospective cohort study of 2,313 middle-aged men aged ≥50 recruited in 1970-73, 421 cases of stroke or transient ischemic attack were observed over a 32-year follow-up [3] . At the baseline visit, cholesterol ester proportions of fatty acids were measured by gas chromatography. The authors found no association between baseline proportions of 14:0 (OR: 1.07; 95% CI: 0.97 to 1.18) or 16:0 (RR: 1.07; 95% CI: 0.96 to 1.20) and risk of ischemic stroke.
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Evidence on saturated fat that was reviewed, but that did not directly inform the GRADE evidence summary
Results from Prospective Cohort Studies

Polyunsaturated:Saturated Fat and all-cause and CVD mortality
The Kuopio Ischaemic Heart Disease Risk Factor Study (IHD), a prospective population-based study including 1551 men followed for a median of 14.6 years (NOS quality=9), observed 78 deaths from cardiovascular disease and 225 total deaths [1] . Dietary fatty acid intake was assessed at baseline using a 4-day diet record, and serum fatty acids were measured by gas chromatography. A dietary polyunsaturated:saturated fat (P:S) ratio in the upper third was associated with a 29% reduction in risk of all-cause mortality in age-adjusted models (RR: 0.71; 95% CI: 0.51 to 0.98), the association was not significant after adjustment for other risk factors. A serum P:S ratio in the upper third was associated with a 31% reduction in all-cause mortality (OR: 0.69; 95% CI: 0.41 to 1.03). A dietary P:S ratio in the upper third was associated with a 56% reduction in all-cardiovascular mortality (fully MV adjusted OR: 0.44; 95% CI: 0.20 to 1.00). A serum P: S ratio in the upper third was associated with a similar 60% reduction in risk of CVD mortality (OR: 0.40; 95% CI: 0.18 to 0.87), but was no longer significant when adjusted for measures of adiposity.
This study was not included in our quantitative synthesis because it did not present relative risk for higher vs. lower saturated fat intake; the P: S ratio is affected both by polyunsaturated and saturated fat.
Saturated Fatty Acid Isomers and CHD
The strongest epidemiologic evidence to date for the effects of specific food sources of saturated fatty acids on cardiovascular health comes from the Nurses' Health Study, a prospective cohort study of 80,082 women aged 34-59 y [2] . During 14 years of follow-up, the investigators documented 939 new cases of major CHD events. Food intake was measured by a validated semiquantitative food-frequencyquestionnaire administered in 1980, 1986, and 1990 . The major sources of saturated fat in this population were beef (13%), and hard cheese (11%). Five groups of fatty acids were examined: 4:0 to 10:0 (found mainly in hard cheese, butter, and milk), 12:0 (found mainly in coffee whitener, hard cheese, and low-fat milk), 14:0 (found mainly in hard cheese, beef, low-fat milk, and butter), 16 :0 (found mainly in beef, and hard cheese), and 18:0 (found mainly in beef and hard cheese). In multivariableadjusted models, no significant associations between individual saturated fatty acids and CHD risk were found (Appendix D, Table D1 ). The authors additionally estimated the MVRR for a 1% increase in each fatty acid class, substituted for carbohydrate, and the effect of replacement of 12:0 to 18:0 saturated fatty acids with carbohydrate, monounsaturated fat, or polyunsaturated fat (Table D2) , and found that substitution of longer-chain saturated fatty acids (12:0 to 18:0) with carbohydrate were associated with reduced CHD risk; stronger associations were found when unsaturated fats replaced these isomers of saturated fatty acids. This study was not included in our quantitative synthesis because it was the lone prospective cohort study to assess individual isomers of saturated fat with CHD risk.
In the Zutphen Elderly Study (ZES) [7] , a prospective study of 686 elderly men from the Netherlands, aged 65-85 at baseline, with a range of 14-22% intake of energy from saturated fat, 132 incident CHD events were observed over 15y of follow-up. In this study, no single food source of SFA (butter, dairy, or meat) were significantly associated with CHD, comparing the top to bottom tertiles. Individual FA risk estimates from these studies were not included in our quantitative synthesis because estimates for total SFA were also provided; these were included.
Saturated fat and CVD and mortality in high-risk subgroups
Saturated Fat and Total and Cardiovascular Mortality in diabetes
In a subset of 5,672 participants in the Nurses' Health Study, Tanasescu et al. [8] examined the association between saturated fat intake and CVD risk in women with type 2 diabetes. Over 18 years of follow-up, between 1980 and 1998, they observed 619 new cases of CVD, defined as non-fatal myocardial infarction, fatal CHD, or stroke. Diet was assessed at baseline, and at 4 follow-up occasions using a validated semiquantitative food frequency questionnaire. Replacement of 5% of energy from carbohydrate with saturated fat was associated with a 29% increased risk of CVD (RR: 1.29; 95% CI: 1.02, 1.63). This effect was stronger than what was seen in the entire NHS cohort, which may reflect the adverse effects of saturated fat on lipoproteins, or other metabolic sequelae of insulin resistance, such as blunting of insulin sensitivity.
This study was not included in our main quantitative synthesis because it examined the effect of SFA on CVD mortality in people with type 2 diabetes, a sample which would not be generalizable to the target population for guidelines (generally healthy individuals).
Trichopoulou et al. [9] followed 1,013 participants with type 2 diabetes enrolled in the Greek EPIC cohort from 1993 to mid-2004. Diet was assessed at baseline with a validated 150-item food-frequency questionnaire. Over a median of 4.5 years of follow-up, 80 deaths were observed, 46 of which were from cardiovascular causes. In this study, a 10-g increase in saturated fat intake was associated with an 82% increased risk of all-cause mortality (HR: 1.82; 95% CI: 1.14, 2.90), adjusted for gender, age, education, smoking, waist-to-height, hip circumference, total energy, insulin use, hypertension, and hypercholesterolemia. This study was not included in our main quantitative synthesis because it examined the effect of SFA on CVD mortality in people with type 2 diabetes, a sample from which results would not be generalizable to the target population for guidelines (generally healthy individuals).
In the EURODIAB prospective study of complications of diabetes [10] , 2,108 people with type 1 diabetes were followed for 7 years, during which time 148 incident cases of fatal and non-fatal CVD, and 46 allcause deaths were documented. Diet was assessed once at baseline using a 3-day diet record. In multivariable-adjusted models, a high (45.5 g) intake of saturated fat was not associated with increased risk of CVD in this high risk cohort (RR: 0.84; 95% CI: 0.53 to 1.32; P for trend=0.43). A 10-g increase in saturated fat was not associated with increased CVD risk (RR: 0.85; 95% CI: 0.69 to 1.05) or all-cause mortality (HR: 0.70; 95% CI: 0.48 to 1.04). Substitution models were also explored, and failed to find a significant impact on CVD risk of exchanging saturated fat for other nutrients in type 1 diabetes (Table  D5) 
Saturated Fat and Total and Cardiovascular Mortality in Secondary Prevention
In 285 men and 130 women participating in the EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) study [11] , diet was measured by 4-d food records, and validated against fatty acid composition of serum cholesteryl esters. During 5y of follow-up, 36 participants died, 21 had an MI, and 12 had strokes. For a 1-SD increase in saturated fat (as measured by a 4-d food record), a 57% increase risk of death was observed (RR: 1.57; 95% CI: 1.13 to 2.17), but not specifically due to coronary disease (RR for coronary death: 1.01; 95% CI: 0.61 to 1.69), and there was no increased risk of any coronary (RR: 1.00; 95% CI: 0.68 to 1.46) or cardiovascular events (RR: 1.23; 95% CI: 0.89 to 1.68; for a composite of CVD death, acute MI, and stroke).
In an analysis of the Western Norway B-Vitamin Intervention Trial, which enrolled 2412 participants, 292 of which experienced one coronary event during a mean of 4.8 y follow-up, saturated fat was not associated with risk of coronary events (HR: 0.83; 95% CI: 0.59 to 1.16 
Results from Retrospective Case-Control Studies
Case-Control Studies
Case-control studies were not included in our GRADE assessment of the evidence because higher-quality levels of observational evidence, specifically prospective cohort and prospective nested case-control or case-cohort designs are available.
Saturated Fat and All-Cause Mortality
We did not identify any case-control studies that examined the association between saturated fat intake and all-cause mortality.
Saturated Fat and CHD Mortality
In a nested case-control study conducted within the Whitehall study [12] (NOS quality=6), Clarke et al. compared phospholipid fatty acid concentrations, measured by gas chromatography, between 116 cases of CHD death (aged≈80) and 239 controls frequency matched on age and employment grade. In analyses adjusted only for the matching factors, being in the top quartile of phospholipid saturated fatty acids was associated with twofold higher risk of CHD death (OR: 2.12; 95% CI: 1.13, 3.99; P trend =0.02); further adjustment for biomarkers of CVD risk, however, attenuated this association (OR: 1.77; 95% CI: 0.89 to 3.51; P=0.10), suggesting that the adverse effects of SFA on risk are, at least in part, mediated by the traditional CHD risk factors. This study was included in a sensitivity analysis including nested-case control with prospective cohort studies of saturated fat and CHD death (eFigure 51).
Polyunsaturated:Saturated Fat and all-cause and CVD mortality
A case-control study conducted within the Eastern Finland Heart Survey (92 cases and 92 controls; NOS quality=6) reported the association between the serum P:S ratio (fatty acids measured by gas chromotography) and coronary artery disease mortality [13] . In a multivariable model adjusting for matching factors (smoking, sex, age, serum cholesterol, MAP, and history of CVD), alcohol, work absenteeism, diabetes, family history of MI, medication use, a serum P:S ≤0.28 was associated with a 5.7 (95% CI: 2.0 to 16.4) increased odds of coronary death, independent of serum lipid levels, which may relate to an effect of the balance of fatty acids on prostacyclin/thromboxane A2 synthesis.
Saturated Fat and Total CHD
Total Saturated Fat
We identified 4 retrospective case-control studies or nested-case control studies (n=2,700 cases and 5,306 controls; NOS≥6) reporting the association between total saturated fat, as measured by food frequency questionnaires [14 15 ] or biomarkers [16 17] , and total CHD. The summary OR of high versus low saturated fat is 1.36 (95% CI: 0.96, 1.92; P=0.35; P=0.09; P het =0.35; I 2 =9%) ( Figure D4 ). The majority of the weight (69%) was carried by one study; 2 studies reported borderline positive associations (prospective, nested case-control biomarker studies); and 2 reported no association with wide confidence limits (retrospective case-control FFQ studies). In a fixed-effect model (Figure D5) 
Dose-Respose association of Saturated Fat With Health Outcomes and Substitution effects
Dose-response effects are nuanced when discussing energy-yielding macronutrients, such as saturated fat, as the aim of this type of analysis is to assess the effects of increasing the nutrient, without increasing total food energy. Controlling for total energy in multivariable regression models typically accomplishes this; however, this raises the simple question of which nutrient is exchanged for saturated fat. The most common approach is to construct models such that the dose coefficient is interpretable as a 1% increase in energy from the nutrient of interest, and an equal 1% reduction in energy from another nutrient, usually carbohydrate; but other models may be interpreted differently, as described below.
Prospective Cohort Studies
The continuous association of saturated fat with risk of CHD events and death was directly measured in 4 publications, none of which found significant dose-response effects of increasing saturated fat intake (as a percent of energy) at the expense of total carbohydrate (Tables D6 and D7).
Overall, the strongest epidemiological evidence to-date for the effects of isocaloric substitution of saturated fat for other macronutrients comes from the pooled analysis of 11 prospective cohort studies from the United States of America and Europe in the Pooling Project of Cohort Studies on Diet and Coronary Disease, including 344,696 people followed for 4-10 y, with 5,429 coronary events and 2,155 coronary deaths [32] . This project allowed the investigators to study the associations between major types of dietary fat and CHD risk in different populations, with differing diets and a broad range of nutrient intakes. Study-specific natural logarithms of the individual study HRs were weighted by the inverse of their variances, and a pooled estimate of the HRs was obtained with a random-effects model. The possibility of effect modification by age at study entry (<60 vs. ≥60 y.o.) and sex were also examined, but no evidence was found. Tables D8 and D9 list the HR for coronary events and deaths for the replacement of 5% of energy from total saturated fat with 5% of another macronutrient.
Saturated Fat for Carbohydrate on CVD: The Role of Carbohydrate Quality
Hu et al. [33] first examined the impact of substitution of saturated fat for carbohydrate on CHD risk, in a 14y. prospective cohort study of 80,082 women aged 34-59 years old at entry, with no previous CHD, diabetes, or cancer. Dietary information was collected using a validated food-frequency-questionnaire, and updated in 1986 and 1990. Using updated dietary information, the multivariable adjusted RR for the substitution of 5% of energy from saturated fat with carbohydrate was 0.85 (95% CI: 0.71, 1.03; P=0.10), which was similar to the association observed when only baseline dietary data were used (RR: 0.88; 95% CI: 0.75, 1.03; P=0.12).
While the effect of replacing saturated fat with polyunsaturated fat was found to be the most protective in both the pooling project, replacement of saturated fat with carbohydrate was less consistently associated with benefit, suggesting that there may be important differences in the effects of carbohydrate not captured by the concept of total carbohydrate. The dietary glycemic index, a tool to classify carbohydrate-containing foods on their ability to raise post-prandial glycemia was developed in 1981 by Jenkins et al. is one method of determining the "quality" of a carbohydrate. In a prospective cohort design, Jakobsen et al. followed 57,063 men and women for a median of 12 y. to determine the risk of first myocardial infarction associated with replacement of saturated fat with either low, medium, or high-glycemic index carbohydrates [34] . Diet was assessed using a validated 192-item semiquantitative food frequency questionnaire at baseline. In this study, no benefit was seen of replacing saturated fat with total carbohydrate (RR: 1.04; 95% CI: 0.92, 1.17). However, important differences were seen when the substitutions were stratified by glycemic index of carbohydrate ( Table  D10 ), indicating that replacement of saturated fat with high-glycemic carbohydrates was associated with icnreased risk of CVD, but replacement with low-glycemic index carboyhdrate was associated with reduced risk.
Saturated Fat for Carbohydrate or Protein on ischemic stroke
In the Framingham Heart Study, a prospective cohort of 832 middle-aged U.S. men, followed for 20 years, Gillman et al. [35] estimated the effect of increasing saturated fat, at the expense of energy from other energy-contributing nutrients, on stroke risk. Diet was measured once at baseline using a 24-hour recall. In this study, a 5% increase in energy from saturated fat (substitution for protein and carbohydrate) was associated with a 42% reduced risk of stroke (RR per 5% increase: 0.58; 95% CI: 0.39, 0.82). Two later studies, however, failed to support this finding. In the Women's Health Initiative Observational Study, Yaemsiri et al. [36] report on 87,025 generally healthy post-menopausal women followed for 7 years. Diet was measured using a validated semi-quantitative FFQ at baseline and 3 years later. The authors noted a non-significant increase in risk of total ischemic stroke with increasing saturated fat intake (substituted for energy-contributing nutrients; RR per 10 g/d: 1.04; 95% CI: 0.96, 1.13). Similarly, He et al. [37] followed-up 43,732 male health professionals for 14 years, measuring diet using a validated FFQ at baseline and 4 and 8 years later. These authors reported no dose-response for a 10% increase in energy from saturated fat (substituted for other energy-containing nutrients) on total ischemic stroke using baseline diet (RR: 1.24; 95% CI: 0.85 to 1.82), updated diet (RR: 1.01; 95% CI: 0.68 to 1.52), or cumulative average diet (RR: 1.10; 95% CI: 0.72 to 1.68).
Saturated Fat for Carbohydrate on type 2 diabetes
Schulze [38] prospectively examined the impact of substitution of saturated fat for carbohydrate in 9,702 men and 15,365 women aged 35-65 and free of diabetes as baseline. Diet was measured with a validated food-frequency questionnaire. Over 10 years of follow-up, 844 incident cases of type 2 diabetes were observed (491 in men and 353 in women). The estimated multivariate RR of type 2 diabetes associated with replacement of 5% of saturated fat with carbohydrate was 0.99 (95% CI: 0.72 to 1.35) for men; 1.12 (95% CI: 0.78 to 1.61) for women; and 1.07 (95% CI: 0.85 to 1.35) for both sexes combined. Figure D1 . Pooled most-adjusted (random effects) risk ratios of total saturated fatty acids and all-cause mortality in primary prevention (n=7 comparisons) and secondary prevention (n=2 comparisons). Figure D2 . Pooled most-adjusted (random effects) risk ratios of total saturated fatty acids and CHD and CVD mortality in primary prevention and secondary prevention. Figure D3 . Pooled most-adjusted (random effects) risk ratios of total saturated fatty acids and total CHD in primary prevention and secondary prevention. Figure D4 . Pooled most-adjusted (random effects) odds ratios of total saturated fatty acids and CHD in 2 retrospective case-control studies and 2 prospective nested case-control studies. Figure D5 . Pooled most-adjusted (fixed effect) odds ratios of total saturated fatty acids and CHD in 2 retrospective case-control studies and 2 prospective nested case-control studies. 
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Results from Prospective Cohort Studies
We included all prospective cohort studies of total TFA and the health outcomes which met our inclusion criteria. Additional data from some of these prospective cohorts was used to characterize dose-response relationships, effects of specific TFA isomers, and substitution effects.
Prospective Cohort Studies of specific trans-unsaturated fatty acid classes and health outcomes
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study The Alpha-Tocopherol, Beta-Carotene Cancer Prevention study (n=21,930 men aged 50-69; Finland) assessed the association between elaidic acid (18:1n9t), the major 18:1 trans-unsaturated fatty acid component of hydrogenated vegetable oils, and fatal CHD events over 6 years of follow-up in middle-aged men [43] . In this prospective study with 635 deaths, those with the highest intake of eliadic acid (Q5; 4.3 g/d) were at 37% increased risk of coronary death (RR: 1.37; 95% CI: 1.07, 1.75; P-trend = 0.002) compared with those with the lowest (Q1; 1.3 g/d). This study was not included in our quantitative synthesis because it was the lone prospective cohort study to assess individual isomers of TFA with CHD death.
The Zutphen Elderly Study
The Zutphen Elderly Study (n=667 men aged 64-84; the Netherlands) examined the association between industrially produced 18:1 trans-unsaturated fatty acids and CHD events [44] . In this prospective study with 98 incident cases in 667 men followed for 10 y., a 0.5% increase in energy from industrially-manufactured 18:1 trans fatty acids was not associated with increased risk of CHD (RR: 1.05; 95% CI: 0.94, 1.17), however the comparatively small sample size makes it difficult to reliably estimate differences in the effect of specific isomers. 
Cardiovascular Health Study
Dose-Response and Substitution Models
Dose-response from prospective cohorts
The strongest evidence of a continuous dose-response effect was seen for CHD mortality (31% increase) and total CHD (25% increase) (eTables 7 and 8). The U.S. cohort studies were the only studies that provided sufficient continuous data to pool associations for ischemic stroke and type 2 diabetes, and in these studies a 2% increase in TFA was associated with a 41% increase in risk of type 2 diabetes (RR: 1.41; 95% CI: 1.20 to 1.67; eTable 9), but not of ischemic stroke (RR: 1.00; 95% CI: 0.76 to 1.30 per 2% energy; eTable 10). To enable comparison across studies which did not provide continuous dose-response data, we also pooled most-adjusted relative risks across non-referent quantiles. The extreme quintile comparison showed the strongest association between TFA and CHD mortality, with risks across Q2 through Q4 relatively stable (Table E1) . For total CHD, all non-referent quantiles of TFA showed an increased risk, with evidence of a graded increase across quintiles (ranging from 1.11 to 1.21). The pooled across-quantile associations between TFA and ischemic stroke and type 2 diabetes, however, demonstrated no clear dose-response effect (Tables E4 and E5 ).
Effect of substitution of trans fats for other nutrients Total CHD
Using data from 2 of the largest prospective cohort studies, Mozaffarian and Clarke [47] reported the adjusted RR of CHD for isocaloric replacement of 2% of energy with saturated fatty acids, monounsaturated fatty acids, or polyunsaturated fatty acids. They found that replacement of 2% of energy from trans fats with saturated fat would reduce CHD risk by 17% (RR: 0.83; 95% CI: 0.75, 0.93), with monounsaturated fat by 21% (RR: 0.79, 95% CI: 0.70-0.88), and polyunsaturated fat by 24% (RR: 0.76; 95% CI: 0.67-0.85). In the present analysis, we found no new evidence that would substantially alter these risks.
Type 2 Diabetes
In the Nurses' Health Study prospective cohort [48] , isoenergetic substitution of 2% of energy from trans fats with carbohydrate was associated with a 28% reduction in risk of type 2 diabetes (RR: 0.72; 95% CI: 0.60, 0.87), and replacing 2% of trans with polyunsaturated fat was associated with a 40% lower risk of diabetes (RR: 0.60; 95% CI: 0.48, 0.75). The effect of replacing trans fat with monounsaturated fat was not directly assessed, but by subtraction of the published coefficients, we estimated that replacement of 2% energy from trans fats with monounsaturated fat to be associated with a ≈ 27% lower risk. The one study that provided substitution effect estimates for high, medium, and low-glycemic index carbohydrates [49] provided imprecise estimates, likely due to low power for comparisons by glycemic index rating.
Ischemic Stroke
We did not identify any prospective cohort which directly assessed the effect of substitution of trans fat for other macronutrients on risk of ischemic stroke, so we were unable to assess the effect of substitution of trans unsaturated fat with other nutrients on risk.
Results from Retrospective Case-Control Studies
Total trans-unsaturated fatty acids and cardiovascular outcomes
In total, twelve retrospective case-control studies provided data on CHD outcomes for quantitative synthesis of trans fats and CHD events ( Table 2) . We did not identify any case-control studies specifically examining the association between total trans fats and ischemic stroke, all-cause mortality, or CHD mortality. The most-adjusted multivariable models in retrospective case-control studies adjusted for a median of 5 covariates (range: 3 to 12). Least-adjusted models produced weaker and non-significant associations, with slightly increased heterogeneity (eTable 4; eFigures 45-47). [50] , conducted in nine European countries between 1991 and 1992, an analysis that excluded the two Spanish centers, which had much lower consumption of 18:1 trans than the other centers was conducted. We also recalculated our effects without these data, and under this condition, the odds ratio is slightly stronger and of borderline significance (1.26; 95% CI: 1.00, 1.58; P=0.05), however heterogeneity still remains high (I 2 =57%; P=0.02). Limiting the analysis to the 3 highest-quality studies (4 comparisons, 2353 cases) did not appreciably change the observed association, but did reduce heterogeneity (RR: 1.06; 95% CI: 0.77 to 1.47; P=0.72; P het= 0.25; I 2 =28%). No single study met our criteria for an influential outlier. There was no evidence of publication bias on inspection of funnel plot, or detected using Egger's (P=0.642) or Begg's tests (P=0.902). Given the high degree of heterogeneity (59%) and a reasonably large number of included studies (n=8), we proceeded with univariate meta-regression to identify study-level characteristics which might explain heterogeneity. We did not identify any evidence of effect modification by any of our pre-specified potential effect modifiers: baseline year of study, continent of conduct, length of follow-up, median age of participants, proportion of smokers in the sample, amount of SFA in reference category, mean saturated or trans fat intake of the population, sex, α-linoleic acid, total polyunsaturated fat, adjustment for total energy, method and frequency of exposure assessment, risk of bias score, and adjustment for lipids or blood pressure (i.e. causal intermediates).
Total CHD
Retrospective Case-Control Studies of 18:2 trans-unsaturated fatty acid isomers and cardiovascular outcomes Total CHD
The pooled adjusted odds ratio of high versus low total 18:2 trans-fatty acid exposure estimated from 6 published reports (7 comparisons) including 3,428 CHD cases and 3,276 generally age, sex, and neighbourhood-matched controls was 1.82 (95% CI: 1.14, 2.90; P=0.01) with significant heterogeneity across cohorts (I 2 =77%; P=0.0002) (eFigure 43), and some degree of sensitivity to outlier studies.
Removal of any one of 4 studies either decreased or increased the effect estimate by >10%. Limiting the analysis to the 4 highest quality studies (5 comparisons) slightly strengthened the association (RR: 2.27; 95% CI: 1.03, 5.02; P = 0.04; P het = 0.0004; I 2 =80%). There was no evidence of publication bias on inspection of funnel plot, or detected using Egger's (P=0.086) or Begg's tests (P=0.368). Given the high degree of heterogeneity (77%) and a reasonably large number of included studies (n=7), we used univariate meta-regression to identify study-level characteristics which might explain heterogeneity. We did not identify any evidence of effect modification by any of our pre-specified potential effect modifiers: baseline year of study, continent of conduct, length of follow-up, median age of participants, proportion of smokers in the sample, amount of SFA in reference category, mean saturated or trans fat intake of the population, sex, α-linoleic acid, total polyunsaturated fat, adjustment for total energy, method and frequency of exposure assessment, risk of bias score, and adjustment for lipids or blood pressure (i.e. causal intermediates).
Retrospective Case-Control Studies comparing industrially produced trans-unsaturated fatty acids with ruminant-derived trans-unsaturated fatty acids and cardiovascular outcomes
Total CHD
Industrially-produced vs. Ruminant-derived TFA Ascherio et al. [51] measured the associations between both dietary vegetable and animal trans fatty acid intake and CHD in a retrospective study of 239 cases and 282 controls matched for age, sex, and cardiac history. In this analysis, increased vegetable trans fatty acid intake was associated with an almost twofold increase in CHD risk ( 
Ischemic stroke
We did not identify any retrospective case-control studies specifically examining the association between industrially-produced or ruminant-derived trans-unsaturated fatty acids and risk of stroke. Table E5 . Pooled associations between trans-fatty acid intake and type 2 diabetes
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